SCHEMBL24317629

SCHEMBL24317629

COc1ccc(Cc2ccc3c4c(cccc24)NC3=O)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.43
RORC P51449 1/20 0.42
CDK5 Q00535 1/20 0.41
CDK5R1 Q15078 1/20 0.41
MAOA P21397 1/20 0.41
CHEK1 O14757 1/20 0.41
MAPT P10636 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ALDH1A1 P00352 3/20 0.40
TTR P02766 1/20 0.40
GAA P10253 1/20 0.40
LRRK2 Q5S007 1/20 0.40
KDR P35968 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
KDM4E B2RXH2 2/20 0.39
HPGD P15428 2/20 0.39
POLB P06746 1/20 0.39
CASP1 P29466 1/20 0.39
HTT P42858 1/20 0.39
CASP7 P55210 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24317881 0.88 MAPT (0.53) RORCCDK5CDK5R1MAPTSMN1; SMN2
SCHEMBL24317641 0.80 CHEK1 (0.41) CDK5CDK5R1CHEK1MAPTALDH1A1
SCHEMBL24317388 0.79 RXFP1 (0.43) MAPTSMN1; SMN2ALDH1A1GAAKDR
SCHEMBL7300968 0.79 CDK5 (0.50) RORCCDK5CDK5R1ALDH1A1GAA
SCHEMBL22532759 0.78 CDK5 (0.47) CDK5CDK5R1MAPTALDH1A1GAA
SCHEMBL22532698 0.77 KDM4E (0.46) CDK5CDK5R1MAPTALDH1A1GAA
SCHEMBL22549819 0.75 HRH1 (0.50) RORCCDK5CDK5R1MAPTSMN1; SMN2
SCHEMBL24317439 0.75 PARP1 (0.41) CDK5CDK5R1ALDH1A1GAAKDR
SCHEMBL24317645 0.75 MAPT (0.48) RORCCDK5CDK5R1MAPTSMN1; SMN2
Hydrochloric Acid SCHEMBL22533083 0.74 HRH1 (0.49) RORCCDK5CDK5R1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 US disclosed
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 US disclosed
WO-2022081927-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C4 THERAPEUTICS, INC. (US) 2022-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY NFATC1, CTSS, MMP12 MAOB 283/4885RORC 637/4885CDK5 242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.